Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163.

Autor: Skytthe MK; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Pedersen FB; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark., Wernberg CW; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, Denmark., Indira Chandran V; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Krag A; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, Denmark.; Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark., Di Caterino T; Department of Pathology, Odense University Hospital, Odense Denmark., Mandacaru SC; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark., Blagoev B; Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark., Lauridsen MM; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, Denmark., Detlefsen S; Department of Pathology, Odense University Hospital, Odense Denmark.; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., Graversen JH; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Moestrup SK; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.; Department of Biomedicine, Aarhus University, Aarhus Denmark.; Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
Jazyk: angličtina
Zdroj: Gastro hep advances [Gastro Hep Adv] 2023 Mar 08; Vol. 2 (5), pp. 711-720. Date of Electronic Publication: 2023 Mar 08 (Print Publication: 2023).
DOI: 10.1016/j.gastha.2023.03.006
Abstrakt: Background and Aims: Macrophages play an important role in the development of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). In this study, we investigated the hepatic expression of the macrophage scavenger receptor CD163 and the plasma level of its shed soluble form (sCD163) in patients with obesity and NASH, non-NASH NAFLD (NAFL), or healthy livers (no NAFLD).
Methods: Paired liver biopsies and plasma samples were collected from 61 patients with obesity (body mass index ≥35). Hepatic expression of CD163 was analyzed by immunohistochemistry and data-independent acquisition mass spectrometry, whilst plasma levels of sCD163 were determined by enzyme-linked immunosorbent assay and data-independent acquisition mass spectrometry. NAFLD stage and activity were assessed using the Kleiner fibrosis and NASH Clinical Research Network (NAS-CRN) scoring system.
Results: sCD163 turned out as a promising predictor of NASH with an area under the receiver-operating characteristic curve of 0.78 [0.65;0.92] ( P  = .0008 ). sCD163 increased with more severe NAFLD both in univariate (odds ratio [OR] = 3.31[1.80;6.11], P < .001) and multivariable ordinal logistic regression adjusting for NAFLD risk factors (OR = 2.02 [1.03;3.97], P  = .042 ). On the other hand, hepatic expression of CD163 was negatively associated with more severe NAFLD in univariate ordinal logistic regression determined by immunohistochemistry (OR = 0.91[0.84;0.98], P  = .015 ) and proteomics (OR = 0.13[0.02;0.80], P  = .028 ). Taking NAFLD risk factors into account, hepatic expression of CD163 was only associated with the fibrosis stage (OR = 0.01 [0.0003;0.21], P  = .004 ). Accordingly, hepatic CD163 surface expression and sCD163 were negatively correlated (rho = -0.478, P  = .0001 ).
Conclusion: An increased plasma sCD163 and a concurrent decreased hepatic expression of CD163 are strongly associated with NAFLD in obese patients.
(© 2023 The Authors.)
Databáze: MEDLINE
Externí odkaz: